Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System

Angiotensin receptor blockers (ARBs) used in the treatment of hypertension and potentially in SARS-CoV-2 infection exhibit inverse agonist effects at angiotensin AR1 receptors, suggesting the receptor may have evolved to accommodate naturally occurring angiotensin ‘antipeptides’. Screening of the hu...

Cijeli opis

Bibliografski detalji
Glavni autori: Graham J. Moore, Harry Ridgway, Konstantinos Kelaidonis, Christos T. Chasapis, Irene Ligielli, Thomas Mavromoustakos, Joanna Bojarska, John M. Matsoukas
Format: Članak
Jezik:English
Izdano: MDPI AG 2022-07-01
Serija:Molecules
Teme:
COVID-19
angiotensin II
angiotensin II receptors
biased agonism
molecular dynamics (MD)
angiotensin II receptor blockers (ARBS)
Online pristup:https://www.mdpi.com/1420-3049/27/15/4854

Internet

https://www.mdpi.com/1420-3049/27/15/4854

Slični predmeti